Sanofi expands in Alzheimer’s

Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi’s four strategic disease areas, enhances Sanofi’s early-stage pipeline and includes VG 3927, which will be evaluated in a phase II clinical study in Alzheimer’s disease. VG 3927 is an oral small molecule TREM2 agonist. Activating TREM2 is expected to enhance the neuroprotective function of microglia in Alzheimer’s disease. Financial considerations - Under the terms of the merger agreement, Sanofi and Vigil have agreed to the following: Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing, representing an equity value of approximately $470 million (on a fully diluted basis). In addition, Vigil’s shareholders will receive a non-transferrable contingent value right (CVR) per Vigil share, which will entitle its holder to receive a deferred cash payment of $2, conditioned upon the first commercial sale of VG 3927. The companies expect the transaction to close in Q3 2025. The acquisition will not have an impact on Sanofi’s financial guidance for 2025. Vigil’s second molecule program, is not being acquired by Sanofi.